logo
Share SHARE
FONT-SIZE Plus   Neg

Lorus Therapeutics Receives Patent Approval For Anticancer Drug LOR-253

Lorus Therapeutics Inc. (LOR.TO) said Wednesday it has got the approval of the U.S. Patent and Trademark Office for its patent regarding the lead small molecule anticancer drug LOR-253.

The patent, which was originally set to expire in May 2026, was granted a patent adjustment that extends its expiry date to February 2028.

The US patent covers LOR-253 composition of matter and methods of treating cancer. Patents with similar protection for LOR-253 have been issued in Canada and Australia, and are pending in Europe, Japan, and China.

LOR-253 is in a Phase I clinical trial that assesses the safety profile and antitumor activity of LOR-253. Patients with advanced or metastatic solid tumors who are unresponsive to conventional therapy, or for which no effective therapy is available, are currently being recruited for this clinical study.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
IT services provider Computer Sciences Corp (CSC), on Tuesday reported a profit for the third quarter that also trumped estimates, helped largely by lower operating costs that offset 10 percent drop in revenues. Commenting on the results Mike Lawrie said, "In the third quarter, CSC successfully completed... Entertainment giant Walt Disney Co. (DIS) Tuesday reported an increase in first-quarter profit that also trumped Wall Street expectations, as revenues jumped 14 percent on stupendous performance of Star Wars: The Force Awakens. Burbank, California-based Disney's first-quarter profit rose to $2.88... Media conglomerate Viacom, Inc. on Tuesday reported a 10 percent decline in profit for the first quarter from last year, reflecting lower revenues in the Filmed Entertainment and Media Networks segments. However, adjusted earnings per share for the quarter matched analysts' expectations, while revenues missed their estimates.
comments powered by Disqus
Follow RTT